Pomegra
Blue Arbor Technologies closed a $10.5M Series A led by Ottobock to take its RESTORE prosthetic control system toward U.S. clinical trials.
Key Takeaways
- Blue Arbor raised a $10.5M Series A led by prosthetics maker Ottobock in late October 2026.
- Funds go to feasibility studies, an FDA IDE filing and an implantable sensing unit.
- Valuation and other investors were not disclosed.
Lead
Blue Arbor Technologies, a University of Michigan spinout based in Grass Lake, Michigan, has raised $10.5 million in Series A funding led by its strategic partner Ottobock, announced in the last week of October 2026. The money is meant to carry the company's RESTORE Neuromuscular Interface System through feasibility testing and into a U.S. clinical study. Valuation, round terms and any co-investors were not disclosed.
What Does Blue Arbor Build?
Blue Arbor develops an implantable neuromuscular interface that reads signals from a patient's residual muscles and relays them wirelessly to a prosthetic arm. The company says RESTORE is designed to allow independent, simultaneous control of the fingers, wrist and elbow. That is a harder target than the sequential, mode-switching control common in many commercial myoelectric prostheses.
The system comes in two versions. The RESTORE ESU is an external sensing unit, the nearer-term product. The RESTORE ISU is a fully implantable internal sensing unit that remains at the development stage.
The company's founders are Dr. Paul Cederna, Dr. Theodore Küng and Dr. Alex Vaskov. Tod Borton is chief executive. The founders' research draws on nearly two decades of work in neuromuscular science, reconstructive surgery and neural engineering at Michigan.
Who Is Ottobock and Why Is It Leading the Round?
Ottobock is a German maker of prosthetics, neuro-orthotics and wearable bionics, and it is both lead investor and commercial partner. In February 2026 it announced a $5 million investment in Blue Arbor, described at the time as part of a Series A financing, along with a seat on the company's board. Ottobock chief executive Oliver Jakobi said the investment reflects a strategy of deploying capital in areas that complement the core business and offer long-term growth.
A strategic lead cuts both ways. It supplies a likely distribution channel and a buyer that already understands the product. It also means the round lacks a financial lead that has priced the company against competing offers, which may explain why no valuation was published. The extension from $5 million to $10.5 million over eight months suggests the first tranche met its milestones, though the company has not said so.
How Far Along Is the Technology?
Blue Arbor has completed two human implantations. The first took place in December 2025 at the Medical University of Vienna, and the second was also performed there. Two patients is a feasibility-stage sample, not efficacy evidence, and the company has published no outcome data in its funding announcement.
Regulatory groundwork is further along than the clinical data. RESTORE holds an FDA Breakthrough Device Designation and has been accepted into the FDA's Total Product Life Cycle Advisory Program pilot. A separate NIH-funded UG3 study led by the University of Michigan is comparing surface electrodes with implanted ones. The founders have collectively secured more than $60 million in research grants, which means public money has underwritten much of the science to date.
What Will the $10.5 Million Pay For?
The proceeds will fund three things: completing feasibility studies, pursuing an Investigational Device Exemption from the FDA to allow U.S. clinical studies of the ESU, and starting development of the fully implantable ISU. An IDE is the gate to testing in American patients, and the filing is the main near-term proof point for the round.
The budget looks tight for that scope. Device development, implant manufacturing and a clinical program usually cost more than $10 million before a pivotal study, so a further raise or a larger partner contribution is plausible within two to three years. Neither Blue Arbor nor Ottobock has described a next financing.
Competitive Context
Implanted and neural-interface approaches to prosthetic control have drawn academic and venture attention for years, but few have reached routine clinical use. Surface electromyography remains the commercial standard because it needs no surgery. RESTORE has to show that its added control justifies an implant procedure, and the University of Michigan comparison study speaks directly to that question.
What Comes Next for Blue Arbor?
The next test is the IDE decision. A clearance would permit U.S. enrollment and give the company its first data outside the Vienna procedures. A delay or request for more preclinical work would stretch the runway of a round that is small relative to the task.
The ISU is the longer bet. A fully implantable unit removes external hardware but raises the regulatory bar, and its development is only beginning.
Outlook
Blue Arbor now has $10.5 million, a strategic lead with a board seat, two human implantations and an FDA designation. It does not have disclosed valuation, named financial investors or published patient outcomes. The IDE filing and any data from the feasibility studies will show whether Ottobock's backing reflects clinical progress or strategic positioning.
